Product recalls and product liability risks
First written in FY2016. 3 of 6 entries say "Materialised", first in 2026-05-08. Latest entry: FY2026.
Ono Pharmaceutical moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
The whole theme swung hardest in 2026: 11 of 57 companies on the "Worse" side.
12 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「“Other expenses” for the consolidated fiscal year included the following principal item: / ・Loss related to the voluntary recall of certain products: ¥1.4 billion」
A voluntary recall occurred for certain products, and a related loss of ¥1.4 billion was recognized. Product recall risk has materialized. - FY2020MitigatedAnnual report
「Under the policy of “contributing to society by providing a stable supply of pharmaceuticals whose quality is highly assured,” the Group has established a quality system based on its proprietary quality manual and is working continuously to improve the system.」
For product quality and recall risks, the Group explicitly describes a quality system based on its proprietary quality manual and continuous improvement. - FY2018RestatedAnnual report
「There is no guarantee that all products are free from defects or that product recalls will not occur in the future. The Group has insurance for product liability (PL) claims, but there is no guarantee that the insurance will ultimately provide sufficient coverage for the amount of compensation payable.」
The potential insufficiency of coverage for product recalls and PL claims continues to be disclosed. - FY2016First statedAnnual report
「There is no guarantee that all products are free from defects or that product recalls will not occur in the future. The Group has insurance for product liability (PL) claims, but there is no guarantee that the insurance will ultimately provide sufficient coverage for the amount of compensation payable.」
While compliance with quality control standards is described, the potential insufficiency of coverage for product recalls and PL claims is explicitly noted.